Compare

HGH (Somatropin) vs Tesamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

HGH (Somatropin)

89 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 53% · Mixed 34% · Unfavorable overall 13%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
24
Digestive comfort
126
Skin appearance
71
Appetite control
86
Energy
178

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
120
Flushing
25
Headache
36
GI discomfort
82
Dizziness
178

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–3 mg

0.01–0.025 mg
4
0.025–0.05 mg
11
0.05–0.1 mg
14
0.1–0.2 mg
19
0.2–0.4 mg
29
0.4–0.6 mg
24
0.6–1 mg
13
1–2 mg
4
2–3 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing13stacking36side effects19hgh (somatropin)22

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 20 repeat reporters

Tesamorelin

621 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
168
Appetite control
76
Energy
65
Mood
41
Focus
150

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
84
GI discomfort
156
Dizziness
30
Fatigue
36
Nausea
150

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–2 mg

0.01–0.025 mg
4
0.025–0.05 mg
11
0.05–0.1 mg
18
0.1–0.2 mg
25
0.2–0.4 mg
28
0.4–0.6 mg
23
0.6–1 mg
17
1–2 mg
11

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking28side effects11tesamorelin29

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 43% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 32 days · Based on 137 repeat reporters

Sources (9)

Published sources linked on the HGH (Somatropin) and Tesamorelin wiki pages.

  1. PubMed

    Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline

    Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011

    Source
    Wiki study page →
  2. PubMed

    Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis

    Mameli C, Orso M, Calcaterra V, et al. Pharmacological research. 2023

    Source
    Wiki study page →
  3. FDA Drug Label

    EGRIFTA (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2010

    Source
    Wiki study page →
  4. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. FDA Drug Label

    EGRIFTA SV (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2019

    Source
    Wiki study page →
  7. PubMed

    Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

    Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012

    Source
    Wiki study page →